Categories: AppDevelopmentManufacturing
Investors 1
Mentions in press and media 5
| Date | Title | Description |
| 25.06.2026 | C-Ray Therapeutics Receives Radiopharmaceutical Manufacturing Authorization under China's MAH Framework | CHENGDU, China, June 25, 2026 /PRNewswire/ -- On June 23, 2026, C-Ray Therapeutics (Chengdu) Co., Ltd. ("C-Ray Therapeutics") completed on-site inspections conducted by a panel of experts from the Sichuan Provincial Center for Dru... |
| 28.04.2026 | C-Ray Therapeutics Receives FDA Acceptance of Type II Drug Master File for Copper-64 (Cu-64) | DMF No. 43568 is now active and available for reference in global IND and NDA submissions
CHENGDU, China, April 28, 2026 /PRNewswire/ -- C-Ray Therapeutics (Chengdu) Co., Ltd., today announced that its Type II Drug Master File (DMF) for COP... |
| 26.03.2026 | C-Ray Therapeutics and SHINE Technologies Enter Strategic Partnership for Exclusive Distribution of No-Carrier-Added Lu-177 in Mainland China | CHENGDU, China and JANESVILLE, Wis., March 26, 2026 /PRNewswire/ -- C-Ray Therapeutics (Chengdu, China), a global radiopharmaceutical CRDMO, today announced the execution of a Master Radioisotope Supply Agreement with SHINE Technologies, LL... |
| 19.11.2024 | Deals in brief: Portcast raises USD 6.5 million, Secai Marche nets additional Series A funding, Boman Group charts new fund for Australian startups, and more | Portcast raises USD 6.5 million to automate supply chain decisions
Portcast, a Singapore-based logistics tech startup, has closed a USD 6.5 million Series A round led by Susquehanna Asia VC, with participation from Hearst Ventures and Signa... |
| - | C Ray Therapeutics | “Tongrui Biologics-首页” |
Reviews 0
